
UK Public Sector Hold Times Now Worse Than Banks, Claims New 8x8 Survey
The Streetview survey revealed that even when the matter is critical, 31% of respondents will abandon a call within 10 minutes. For an urgent text message, 70% of Brits expect a reply within five minutes.
Less than 0.2% – four people – said they would stay on a call for more than an hour.
Across the UK, people in Cardiff were the most impatient with almost 8% saying they would hang up in under five minutes, compared to 1.4% in Norwich.
Healthcare and government agencies top the frustration list - and women are more annoyed than men
Historically, banks have been on the receiving end of the majority of caller frustration. But with only 28% of respondents citing current frustrations with bank wait times, essential public services now draw the most ire from callers:
35% cite healthcare providers as their top source of hold time frustration.
33% point to national government agencies, such as HMRC and DVLA.
31% name local councils for delays resolving basic issues like council tax or bin and trash collection.
Women reported higher frustration with healthcare wait times than men (41% vs. 28%). While most of the country was aligned in annoyance at wait times, slight regional differences did emerge, with North West residents being the least tolerant of local council delays.
The findings come after an 8x8 survey earlier this year showing that 62% of the UK demands fines for companies that keep them on hold for too long.
'Wait times are a solvable problem'
'UK consumers won't tolerate long wait times or poor call routing for urgent matters,' said Jamie Snaddon, EMEA Managing Director at 8x8, Inc. 'In an age of AI, chatbots, and multiple contact options, wait times are a solvable problem. Businesses need to modernize contact center strategies with intelligent routing, automated callbacks, and real-time messaging to meet rising expectations. Using technology for the simple queries – which normally make up more than half of calls to organizations – frees up human agents to deal with the more complex matters.'
Demand grows for messaging options and faster replies
While 53% still prefer calling for urgent issues, nearly 12% now choose text or WhatsApp. If a call goes unanswered, 41% immediately switch to email, text, or use social media to try and get a resolution.
Expectations for text responses are high:
38% expect a reply within four to five minutes.
25% expect one in two to three minutes.
7% wouldn't wait more than a minute.
Anger is up while spending is down
The findings come just weeks after insights company Tussell and techUK released a Tech Titans report showing that anticipated spending on local government technology solutions is set to decline in the coming years, which will likely increase times and add to frustration.
8x8: working with the private and public sector to bring solutions
8x8 works with a number of organizations in the public and private sector to address problems like wait times and call resolutions through the 8x8 Platform for CX. By seamlessly uniting contact center, unified communications, and communication APIs, the 8x8 Platform for CX helps organizations connect customers and teams around the world, empowering CX leaders with AI-powered performance and insights to make smarter decisions, delight customers, and drive lasting business impact.
To learn more about 8x8's involvement with the public sector, please visit the 8x8 public sector webpage.
Read the full survey and see the mood of the UK
You can find the full survey results here. More than 2000 people were surveyed across the UK in February of 2025.
About 8x8 Inc.
8x8, Inc. (NASDAQ: EGHT) connects people and organizations through seamless communication on the industry's most integrated platform for Customer Experience – combining Contact Center, Unified Communication, and CPaaS solutions. The 8x8® Platform for CX integrates AI at every level to enable personalized customer journeys, drive operational excellence and insights, and facilitate team collaboration. 8x8 helps customer experience and IT leaders become the heartbeat of their organizations, empowering them to unlock the potential of every interaction. For additional information, visit www.8x8.com, or follow 8x8 on LinkedIn, X, and Facebook.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
2 days ago
- Globe and Mail
Bayer AG's Exploratory Study on Sepsis and DIC: A Potential Game-Changer?
Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bayer AG is conducting an exploratory study titled 'Exploratory Study to Investigate the Association Between the Onset of Disseminated Intravascular Coagulation (DIC) and Disease Progression With Different Biomarker Candidates as Well as Standard Clinical and Demographic Parameters in Adult Patients With Sepsis.' The study aims to understand how sepsis progresses to DIC, a severe blood disorder, by identifying biomarkers in patients admitted to intensive care units across Europe. This research is significant due to the limited treatment options for DIC, especially in sepsis patients. The study involves no investigational treatments; instead, participants receive standard medical care for sepsis. The focus is on collecting blood samples and clinical data to identify biomarkers indicative of DIC development. Designed as an interventional study with a single-group model, this research does not involve masking and primarily seeks to gather observational data. The study's primary purpose is to explore the progression of sepsis to DIC. The study began on January 29, 2025, with primary completion expected within 56 days for each participant. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and data collection. This study could impact Bayer's stock performance by potentially enhancing its reputation in the medical research field, especially if the findings lead to improved understanding and treatment of sepsis-related DIC. Investors may view this as a positive development, although the absence of new drug interventions limits immediate commercial implications. The study is ongoing, with further details available on the ClinicalTrials portal.


Globe and Mail
2 days ago
- Globe and Mail
AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical trial titled A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. The study aims to assess the safety and tolerability of the drugs AZD2284, AZD2287, and AZD2275 in treating this aggressive form of prostate cancer. The trial is testing three drugs: AZD2284, AZD2287, and AZD2275, all administered via intravenous methods. AZD2284 is the primary focus, with the goal of determining its optimal dosing and efficacy in conjunction with the other two drugs. This non-randomized, open-label study follows a sequential intervention model. It is primarily focused on treatment, with no masking involved, allowing for direct observation of the drug effects. The study began on March 10, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they indicate the study's progress and the timeline for potential results. This study's update could influence AstraZeneca's stock performance positively, as successful results may enhance investor confidence and market position in the oncology sector. Competitors in the prostate cancer treatment market will be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.


Globe and Mail
2 days ago
- Globe and Mail
AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma. The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule. This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study. The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates to stakeholders. The ongoing study may influence AstraZeneca's stock performance and investor sentiment, as successful outcomes could enhance the company's oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market. The study is ongoing, with further details available on the ClinicalTrials portal.